Massachusetts-based Rational Vaccines Inc. today announced the launch of an observational clinical trial designed to determine the baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex virus type 2 (HSV-2).
In addition to assessing the typical baseline characteristics of a population, the purpose of this study is also to determine the acceptance of clinical trial procedures and understand the interest of the target patient population to participate in a therapeutic Phase 1/2 HSV-2 vaccine study in humans.
Herpes Vaccine Candidate Launches Early-Phase Study
Mental Health Burden Up for Racial, Ethnic Minorities During Pandemic
Positive screens for depression or anxiety more likely for racial/ethnic minorities well into the pandemic
Clinical Guideline Issued for Use of COVID-19 Convalescent Plasma
Strong recommendation based on high-certainty evidence against CCP for unselected hospitalized patients with moderate, severe disease
U.K. Is First Country to Approve Moderna Omicron-Targeted Vaccine
Updated vaccine expected to have ‘important role’ in protecting people from COVID-19 this winter